CRT-401

N/A

Report date: 2026/04/23 20:00:25

Base Information

Drug NameCRT-401
Drug Alias NameCRT-401
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy > In vivo CAR-T therapyCell and gene therapy > Cell therapy > In vivo cell therapy > In vivo CAR-T therapyCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > Natural killer cell therapy > Chimeric antigen receptor NK cell therapy > In vivo CAR-NK therapy
Mechanisms of ActionReceptor protein-tyrosine kinase erbB-2 inhibitorsTumor-associated calcium signal transducer 2 inhibitors
TargetsReceptor protein-tyrosine kinase erbB-2Tumor-associated calcium signal transducer 2
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesCREATE Medicines Inc
China Registration ClassN/A

Develop Information

Active CompaniesCREATE Medicines Inc
Inactive CompaniesN/A
Active IndicationsNeoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A